Efficacy, safety, and cost effectiveness of intravenous midazolam and flunitrazepam for primary insomnia in terminally ill patients with cancer: a retrospective multicenter audit study

Matsuo N, Morita T

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
17985961

DOI
10.1089/jpm.2007.0016

Indexing Status
Subject indexing assigned by NLM

MeSH
Aged; Anti-Anxiety Agents /administration & dosage /adverse effects /therapeutic use; Cost-Benefit Analysis; Female; Flunitrazepam /administration & dosage /adverse effects /therapeutic use; Humans; Japan; Male; Medical Audit; Midazolam /administration & dosage /adverse effects /therapeutic use; Neoplasms /complications; Palliative Care; Retrospective Studies; Sleep Initiation and Maintenance Disorders /drug therapy /economics /etiology; Terminally Ill

AccessionNumber
22007002492

Date bibliographic record published
01/12/2008